A new study at IISc looks to uncover the secret behind the development of drug resistance in TB causing bacteria by testing the efficacy of various commonly available antibiotics. The researchers have found that a combination of commonly available antibiotics along with Augmentin, fights the development of resistance among TB bacteria. This study might throw light on developing new class of drugs that can help contain the spread of deadly tuberculosis, claim the researchers.
You are here
Though our fight against tuberculosis has a long history, we have not been able to wipe off this bacterial infection from the face of the planet. Even to this day, there are numerous studies all over the world that are trying to find the ‘best’ drug against this killer disease. In a new approach to fight tuberculosis, a recent study has now shone some light on how our body fights Mycobacterium, the causative bacteria of TB. Understanding this mechanism, the researchers say, could open up new vaccines and drugs against TB and help us win the seemingly never ending battle.
An increasing number of cases of multi-drug resistant tuberculosis and total-drug resistant tuberculosis are being discovered in India, accounting for the highest TB burden in any country across the globe. It has been said, ‘It is not the strongest species that survive, nor the most intelligent, but the ones most responsive to change’. Mycobacterium tuberculosis is able to adapt and thrive despite the immune system and drugs that are targeted against it. This is due to its ability to sense and adapt to its host's environment. Dr. Deepak Saini’s laboratory at the Indian Institute of Science, Bangalore, is working at unraveling the molecular mechanism that helps M. tuberculosis sense, respond and adapt to its host environment.
The mechanism by which two small molecules work against the bacterium Mycobacterium tuberculosis (Mtb) has been deciphered at IISc. These molecules are in fact antidepressants and their derivatives!